🧫

Meta-analysis of LRP1 C766T polymorphism and Alzheimer's disease susceptibility

active
experiment Created: 2026-04-10T23:13:02 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-21448d10-6b1e-46da-bf4f-9015f3fe1cde
🧫 Experiment Protocol ExploratoryAlzheimer's diseaseLRP1human patientsproposed
This meta-analysis examined the association between the LRP1 C766T polymorphism (rs1799986) and Alzheimer's disease susceptibility across multiple populations. The study included 26 independent case-control studies with a total of 6,455 AD cases and 6,304 controls. The analysis investigated overall associations as well as subgroup analyses by ethnicity (Asian vs other populations) and AD onset type (late-onset vs early-onset). Multiple genetic models were tested including allele model (T vs C), dominant model (TT + CT vs CC), and recessive models. The meta-analysis aimed to resolve contradictory findings from previous individual studies regarding this polymorphism's role in AD risk.
PRIMARY OUTCOME
Association between LRP1 C766T polymorphism and AD susceptibility
EXPECTED OUTCOMES
Clarification of the association between LRP1 C766T polymorphism and AD risk across different populations and AD subtypes
SUCCESS CRITERIA
- Prespecified primary endpoint (Association between LRP1 C766T polymorphism and AD susceptibility) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
Systematic literature review and meta-analysis of case-control studies. Studies were identified and data extracted for genotype frequencies in AD cases versus controls. Statistical analysis included calculation of odds ratios with 95% confidence intervals for different genetic models. Subgroup analyses were performed by ethnicity and AD onset type.
🧫 Experiment Extras
PATHWAY
Low-density lipoprotein receptor pathway
MARKET PRICE
$0.50
STATUS
proposed
Related Target
LRP1composite 0.549
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.